RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors

All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m2/days,-5,-4 days) and fludarabine (25-30mg/m2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.